Siegfried Holding

SFZN.SWPre-clinical

Zofingen, Switzerlandsiegfried.ch

Siegfried is a leading, publicly traded CDMO with a strong heritage and a global network of production and development sites. The company's core mission is to be a reliable, high-quality partner for the pharmaceutical industry, offering end-to-end solutions from drug substance to drug product. Its strategic focus is on complex molecules, including highly potent active pharmaceutical ingredients (HPAPIs) and controlled substances, positioning it in attractive, high-growth market segments. Siegfried's integrated service model and technological expertise support its clients in bringing innovative medicines to market efficiently.

Market Cap

$4.1B

Employees

3500-4000

Focus

Biotech

SFZN.SW · Stock Price

USD 73.10+0.30 (+0.41%)

Historical price data

AI Company Overview

Technology Platform

Integrated contract development and manufacturing organization (CDMO) offering end-to-end services from active pharmaceutical ingredient (API) synthesis to finished dosage form (FDF) production, with specialized expertise in complex molecules including highly potent APIs (HPAPIs) and controlled substances.

Opportunities

Growth is driven by the strong outsourcing trend in pharma, the rise of biotech companies lacking internal manufacturing, and the increasing complexity of new drug molecules, particularly in oncology and rare diseases, which play to Siegfried's specialized expertise.

Geographic expansion and further service integration present additional avenues for growth.

Risk Factors

Key risks include client concentration, operational and regulatory compliance failures, pricing pressure from competitors in low-cost regions, and the cyclical nature of development projects dependent on client pipelines.

Macroeconomic factors like inflation and supply chain disruptions also pose challenges.

Competitive Landscape

Siegfried competes with large global CDMOs like Lonza and Catalent, as well as specialized API manufacturers. Its differentiation lies in its integrated API+FDF service model, niche expertise in handling highly potent and controlled substances, and the strong quality reputation associated with its Swiss heritage and global regulatory track record.

Publications